Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical has announced the composition of its board of directors, which includes a mix of executive, non-executive, independent non-executive, and employee directors. The board is supported by five specialized committees, each chaired and populated by different board members, indicating a structured approach to governance and strategic oversight.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products and healthcare services.
Average Trading Volume: 11,635,533
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.13B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.